Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07122882) titled 'Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance' on Aug. 8.
Study Type: Observational [Patient Registry]
Primary Sponsor: Chang Gung Memorial Hospital
Condition:
Oncogene-addicted Non Small Cell Lung Cancer
EGFR Mutation
ALK Fusion-positive Solid or CNS Tumors
ROS1 Fusion Positive
RET Fusion Positive
ERBB2 Mutation-Related Tumors
NTRK1 Fusion Positive
NTRK2 Fusion Positive
NTRK3 Fusion Positive
NRG1 Fusion
BRAF V600 Mutation
KRAS G12C Mutation
MET Exon 14 Skipping Mutation
Recruitment Status: Not recruiting
Date of First Enrollment: September 1, 2025
Target Sample Size: 40
To know more,...